Table 4.

Base–case analysis for incremental cost-effectiveness (cost per life year and QALY gained)

	Denosumab vs. no treatment	Denosumab vs. generic alendronate	Denosumab vs. risedronate	Denosumab vs. strontium ranelate
Costs/patient (€)
Morbidity cost difference	−2,181	−1,148	−1,403	−1,664
Treatment cost differencea	1,868	1,529	1,055	939
Cost in added life years	1,087	649	745	768
Total cost difference	774	1,030	397	43
Avoided fractures during 10 years/1,000 patients
Hip fractures	−39	−20	−26	−32
Vertebral fractures	−62	−41	−45	−43
NNT to avoid one hip fracture	26	50	39	32
NNT to avoid one vertebral fracture	17	25	23	24
QALYs and life years/patient
Life years gained (undiscounted)	0.068	0.040	0.046	0.048
Life years gained (discounted)	0.047	0.028	0.032	0.033
QALYs gained	0.084	0.049	0.057	0.060
Cost/life year gained	16,531	37,082	12,409	1,290
Cost per QALY gained (excluding CIALY)	Cost saving	7,764	Cost saving	Cost saving
Cost per QALY gained	9,250	20,976	6,998	710

Women aged 71 years with a T-score at or below −2.5 SD and 34% prevalence of prior vertebral fracture

NNT number needed to treat

^aIncluding monitoring costs